NEW YORK, May 2, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
How to find trends and revenue predictions for the ophthalmic drug industry
What are the commercial prospects for treating eye disorders? Visiongain's report shows you potential revenues to 2022 - data, forecasts and discussions.
This study investigates prescription drugs treating human eye diseases. It lets you assess forecasted sales trends at world market, therapeutic submarket, product and national level to 2022.
How will 20 leading ophthalmic drugs - including Lucentis, Visudyne, Xalatan/Xalacom and Restasis - perform from 2012? Our investigation gives you business research and analysis with sales forecasts.
You also see forecasting of five submarkets to 2022, finding potential revenues:
• Glaucoma treatments
• Anti-allergy, anti-inflammatory and anti-infective agents
• Retinal disorder treatments
• Dry eye treatments
• Other medicines.
Find coverage of the R&D pipeline too, by therapeutic area, assessing trends and outlooks.
What will happen next? The pharma industry will improve treatment of ocular disorders and increase revenues there. The R&D pipeline in ophthalmology is strong. Also, improved drug delivery and new formulations will be important.
Visiongain predicts that the world market for ocular drugs will grow strongly from 2012 to
Copyright©2010 PR Newswire.
All rights reserved